Future research should focus on elucidating the precise mechanisms of COL22A1-mediated PI3K/AKT activation, exploring its therapeutic potential, and investigating its role in treatment resistance and tumor microenvironment modulation in GBM. The gene discussed is AKT1; the disease is glioblastoma.